EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): AGMEGM
Relief Announces Notice of Extraordinary General Meeting of RELIEF
THERAPEUTICS Holding AG
2020-11-23 / 07:00
*Relief Announces Notice of Extraordinary General Meeting of *
*RELIEF THERAPEUTICS Holding AG*
*Geneva, Switzerland, November 23, 2020 -* RELIEF THERAPEUTICS Holding AG
(SIX: RLF, OTCQB: RLFTF) ("*Relief*" or the "*Company*"), a
biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in
advanced clinical development to treat severe COVID-19 patients, today gives
notice of an Extraordinary General Meeting (EGM) of shareholders to be held
on December 17, 2020.
As a result of the exceptional circumstances due to the coronavirus
pandemic, the EGM will be held without the physical presence of
shareholders, representatives and third parties in accordance with the
requirements of the Ordinance of the Swiss Federal Council regarding
measures on combatting the coronavirus. Shareholders are able to exercise
their voting rights through giving all voting instructions to the
independent proxy, Mr. Thomas Hua. Guidelines on how to deliver voting
instructions can be found in the EGM formal invitation, which will be sent
out within the next few days to registered shareholders. Instructions
transmitted electronically should be executed no later than December 14,
2020, 23:59 (CET).
*Entitlement to vote *
Those shareholders who are registered in the share register as of December
4, 2020, 13:00 (CET), are entitled to vote. No registration in the share
register will be made from December 4 through December 17, 2020.
Shareholders who sell all or part of their shares prior to the General
Meeting will no longer be entitled to vote to that extent.
1. Election of the Chair of the Extraordinary General Meeting
2. Election of Tom Plitz as new member of the Board of Directors
3. Votes on the compensation of the members of the Board of Directors and of
the Executive Committee
4. Increase of authorized share capital
5. Increase of conditional share capital 3b2
The full agenda is available for download on the Company's website
*Election of Tom Plitz as new member of the Board of Directors*
Tom is Chief Executive Officer of Chord Therapeutics SA, a privately held
biopharmaceutical firm based in Geneva, Switzerland. He has more than two
decades of experience in pharmaceutical R&D, most recently as Chief
Scientific Officer of the rare disease company Wilson Therapeutics. Wilson
Therapeutics was acquired for USD 855 million by Alexion Pharmaceuticals in
April 2018. Tom's previous assignments include senior roles at Serono,
Merck, and Shire, where he worked across multiple therapeutic areas,
including neuroinflammatory, metabolic, and rare diseases. Tom holds a Ph.D.
from Technical University of Munich, Germany.
*Votes on the compensation of the members of the Board of Directors and of
the Executive Committee*
The Board of Directors recommends adjusting the compensation pool available
for the remuneration of its members in the ongoing financial year from CHF
1,000,000 (as previously accepted by July's AGM) to CHF 1,500,000.
Furthermore, with the rapid development of the Company and its activities
over the last months, the Board of Directors has reinforced, and will
continue to reinforce, the Relief management team. Therefore, a request is
made for the approval of a compensation pool of CHF 5,000,000 for management
remuneration for the financial year 2021.
*Increase of authorized capital and of conditional share capital 3b2*
The authorized share capital is intended for the future financing of the
Company, as required in connection with future projects as well as for
responding quickly to strategic business opportunities. An increase from
1,056,726,052 shares to 1,250,000,000 shares will provide the Company
additional flexibility to raise capital or pursue acquisitions.
An increase of the conditional share capital from 740,329,636 shares to
960,000,000 shares will provide additional flexibility should the Company
need to use financing instruments with conversion features. This measure is
being put in place as a precaution and to ensure adequate funds to complete
all study plans for RLF-100TM. As further explained in the EGM invitation,
the resulting available number of conditional shares will be 340,000,000
shares as recent issuances of 620,000,000 new shares out of the conditional
share capital 3b2 are not yet reflected in the Articles of Association.
Relief focuses primarily on clinical-stage programs based on molecules of
natural origin (peptides and proteins) with a history of clinical testing
and use in human patients or a strong scientific rationale. Currently,
Relief is concentrating its efforts on developing new treatments for
respiratory disease indications. Its lead drug candidate RLF-100TM
(aviptadil), synthetic vasoactive intestinal peptide (VIP), is being
investigated in two placebo-controlled U.S. Phase 2b/3 clinical trials in
respiratory deficiency due to COVID-19. RLF-100TM is believed to be the
first COVID-19 therapeutic to demonstrate the ability to block replication
of the SARS-CoV-2 virus in human lung cells and monocytes, while also
preventing synthesis of cytokines in the lung. Since July 2020, severe
COVID-19 patients have been treated with RLF-100TM under U.S. FDA Emergency
Use Investigational New Drug (IND) authorization and Expanded Access
Protocol authorization for the treatment of respiratory failure in COVID-19.
Relief also holds a patent issued in the United States and various other
countries covering potential formulations of RLF-100TM.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the
symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF.
Follow us on *LinkedIn *
*CONTACT *FOR MEDIA/INVESTOR
RELIEF THERAPEUTICS Holding AG* INQUIRES:
Raghuram (Ram) Selvaraju, Ph.D., MC Services AG*
MBA Anne Hennecke / Brittney
Chairman of the Board Sojeva
Mail: Mail: firstname.lastname@example.org
www.relieftherapeutics.com Tel.: +49 (0) 211-529-252-14
Disclaimer : This communication expressly or implicitly contains certain
forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors, which could cause the actual results,
financial condition, performance or achievements of RELIEF THERAPEUTICS
Holding AG to be materially different from any future results, performance
or achievements expressed or implied by such forward-looking statements.
RELIEF THERAPEUTICS Holding AG is providing this communication as of this
date and does not undertake to update any forward-looking statements
contained herein as a result of new information, future events or otherwise.
End of Media Release
Company: RELIEF THERAPEUTICS Holdings AG
Avenue de Sécheron 15
Listed: SIX Swiss Exchange
EQS News ID: 1149786
End of News EQS Group News Service
(END) Dow Jones Newswires
November 23, 2020 01:00 ET (06:00 GMT)